NCT04358393 - A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

AMLAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaCMMLMyelodysplastic SyndromesHigh-risk Myelodysplastic SyndromeMDS

Interventions

DRUG

APG-115

APG-115 given once daily on day 1-5 of every 28 day cycle

DRUG

5-azacitidine

5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days

Trial Locations (8)

RECRUITING

Virginia Cancer Specialists, Fairfax

RECRUITING

Duke University, Durham

RECRUITING

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

RECRUITING

Texas Oncology - Tyler, Tyler

RECRUITING

MD Anderson, Houston

RECRUITING

Rocky Mountain Cancer Centers, Denver

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

RECRUITING

Seattle Cancer Care Alliance, Seattle